Tenofovir Activating Kinases May Impact the Outcome of HIV Treatment and Prevention

Tenofovir Activating Kinases May Impact the Outcome of HIV Treatment and Prevention

Bibliographic Details
Main Authors:	Dimitri Topalis, Robert Snoeck, Graciela Andrei
Format:	Article
Language:	English
Published:	Elsevier 2015-09-01
Series:	EBioMedicine
Subjects:	Tenofovir activation HIV Pre-exposure prophylaxis Nucleotide kinases
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352396415300943

Similar Items

Discovery of Genetic Variants of the Kinases That Activate Tenofovir in a Compartment-specific Manner
by: Julie M. Lade, et al.
Published: (2015-09-01)

Tenofovir-Diphosphate as a Marker of HIV Pre-exposure Prophylaxis Use Among East African Men and Women
by: Maria Pyra, et al.
Published: (2019-04-01)

Plasma pharmacokinetics and urinary excretion of tenofovir following cessation in adults with controlled levels of adherence to tenofovir disoproxil fumarate
by: Tim R. Cressey, et al.
Published: (2020-08-01)

A randomized clinical pharmacokinetic trial of Tenofovir in blood, plasma and urine in adults with perfect, moderate and low PrEP adherence: the TARGET study
by: Tim R. Cressey, et al.
Published: (2017-07-01)

Multispecies Evaluation of a Long-Acting Tenofovir Alafenamide Subdermal Implant for HIV Prophylaxis
by: Manjula Gunawardana, et al.
Published: (2020-11-01)

Bictegravir Plus Tenofovir Alafenamide Nanoformulation as a Long-Acting Pre-Exposure Prophylaxis Regimen: Application of Modeling to Design Non-Human Primate Pharmacokinetic Experiments
by: Simone Perazzolo, et al.
Published: (2020-12-01)

PrEP uptake and adherence in relation to HIV-1 incidence among Kenyan men who have sex with men
by: Elizabeth W. Wahome, et al.
Published: (2020-09-01)

Frequency of Hepatitis B Virus Resistance Mutations in Women Using Tenofovir Gel as Pre-Exposure Prophylaxis
by: Cheryl Baxter, et al.
Published: (2019-06-01)

Perspectives on the utility and interest in a point-of-care urine tenofovir test for adherence to HIV pre-exposure prophylaxis and antiretroviral therapy: an exploratory qualitative assessment among U.S. clients and providers
by: Ashley R. Bardon, et al.
Published: (2020-08-01)

Performance and Stability of Tenofovir Alafenamide Formulations within Subcutaneous Biodegradable Implants for HIV Pre-Exposure Prophylaxis (PrEP)
by: Linying Li, et al.
Published: (2020-11-01)

Pre-exposure prophylaxis for the prevention of HIV infection: a new prevention paradigm?
by: Javier Sánchez-Rubio Ferrández, et al.
Published: (2016-05-01)

Monitoring the Effects of Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Switch for Tubulotoxicity in Highly Treatment-Experienced or in Very Sick Individuals Infected with HIV
by: Nicole Marie Lioufas, et al.
Published: (2018-06-01)

Pilot evaluation of an enzymatic assay for rapid measurement of antiretroviral drug concentrations
by: Ayokunle O. Olanrewaju, et al.
Published: (2021-04-01)

Tenofovir Disoproxsil Fumarate in the Treatment of AIDS
by: Kubra Kurt, et al.
Published: (2015-03-01)

Adolescent pre-exposure prophylaxis for HIV prevention: current perspectives
by: Machado DM, et al.
Published: (2017-11-01)

Pre-exposure prophylaxis for HIV prevention in women: current perspectives
by: Flash CA, et al.
Published: (2017-05-01)

Failure of pre-exposure prophylaxis with daily tenofovir/emtricitabine and the scenario of delayed HIV seroconversion
by: Shui-Shan Lee, et al.
Published: (2020-05-01)

Renal function change after switching tenofovir disoproxil fumarate for tenofovir alafenamide in the HIV-positive patients of a metropolitan sexual health service
by: Dane Turner, et al.
Published: (2019-12-01)

InterPrEP. Internet-based pre-exposure prophylaxis with generic tenofovir DF/emtricitabine in London: an analysis of outcomes in 641 patients
by: Isaac Aloysius, et al.
Published: (2017-10-01)

Transmitted drug resistance to Tenofovir/Emtricitabine among persons with newly diagnosed HIV infection in Shenyang city, Northeast China from 2016 to 2018
by: Zhen Wang, et al.
Published: (2021-07-01)

Knowledge of PEP and PrEP among people living with HIV/aids in Brazil
by: Laelson Rochelle Milanês Sousa, et al.
Published: (2021-01-01)

Characterization of a Reservoir-Style Implant for Sustained Release of Tenofovir Alafenamide (TAF) for HIV Pre-Exposure Prophylaxis (PrEP)
by: Leah M. Johnson, et al.
Published: (2019-07-01)

Development and evaluation of mucoadhesive bigel containing tenofovir and maraviroc for HIV prophylaxis
by: Margaret O. Ilomuanya, et al.
Published: (2020-11-01)

How safe is TDF/FTC as PrEP? A systematic review and meta-analysis of the risk of adverse events in 13 randomised trials of PrEP
by: Victoria Pilkington, et al.
Published: (2018-10-01)

Trends in HIV pre-exposure prophylaxis use in eight Canadian provinces, 2014–2018
by: Qiuying Yang, et al.
Published: (2021-05-01)

Evaluation of cardiovascular biomarkers In HIV-infected patients switching to abacavir or tenofovir based therapy
by: Langdahl Bente L, et al.
Published: (2011-10-01)

Perceptions about HIV pre-exposure prophylaxis among healthcare professionals in Spain (PERPPRES Study)
by: Javier Sánchez-Rubio Ferrández, et al.
Published: (2016-07-01)

The demographic features and outcome indicators of the Barbados HIV Pre-exposure Prophylaxis Program, 2018-2019
by: Anton Best, et al.
Published: (2021-04-01)

Urine Assay to Measure Tenofovir Concentrations in Patients Taking Tenofovir Alafenamide
by: Linden Lalley-Chareczko, et al.
Published: (2020-03-01)

Adenosine Deaminase as a Biomarker of Tenofovir Mediated Inflammation in Naïve HIV Patients
by: Francisco Miguel Conesa-Buendía, et al.
Published: (2020-05-01)

Renal function in Ethiopian HIV-positive adults on antiretroviral treatment with and without tenofovir
by: Daniel Yilma, et al.
Published: (2020-08-01)

Single oral dose for HIV pre or post-exposure prophylaxis: user desirability and biological efficacy in macaques
by: Ivana Massud, et al.
Published: (2020-08-01)

Changing trends in lipid profile and biomarkers of renal function and bone metabolism before and after switching from tenofovir disoproxil fumarate to tenofovir alafenamide: a prospective observational study
by: Mahoko Ikeda, et al.
Published: (2021-05-01)

Lamivudine plus tenofovir combination therapy versus lamivudine monotherapy for HBV/HIV coinfection: a meta-analysis
by: Aoran Luo, et al.
Published: (2018-09-01)

Spatial analysis of factors associated with HIV infection in Malawi: indicators for effective prevention
by: Jerry John Nutor, et al.
Published: (2020-07-01)

Perceived risk versus objectively measured risk of HIV acquisition: a cross-sectional study among HIV-negative individuals in Serodiscordant partnerships with clients attending an Urban Clinic in Uganda
by: Lillian Tugume, et al.
Published: (2019-11-01)

Pre-exposure prophylaxis (PrEP) against HIV: efficacy, safety and uncertainties
by: Santiago Moreno Guillen, et al.
Published: (2017-09-01)

Baseline Preferences for Daily, Event-Driven, or Periodic HIV Pre-Exposure Prophylaxis among Gay and Bisexual Men in the PRELUDE Demonstration Project
by: Stefanie J. Vaccher, et al.
Published: (2017-12-01)

Pre-Exposure Prophylaxis (PrEP) in the Prevention of HIV: Strategies, Target Populations and Upcoming Treatments
by: Özdener-Poyraz AE, et al.
Published: (2020-07-01)

HIV Prevention After Discontinuing Pre-Exposure Prophylaxis: Conclusions From a Case Study
by: Kai J. Jonas, et al.
Published: (2018-05-01)

Cannot write session to /tmp/vufind_sessions/sess_uqu3c6d5oaafp7m0jksi8f81av